See more : Al Ashghal Al Moysra Co. (9608.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Syndax Pharmaceuticals, Inc. (SNDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Syndax Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lets Holdings Group Co., Ltd. (002398.SZ) Income Statement Analysis – Financial Results
- Netweb Technologies India Limited (NETWEB.NS) Income Statement Analysis – Financial Results
- nDatalyze Corp. (NDATF) Income Statement Analysis – Financial Results
- Astellas Pharma Inc. (ALPMF) Income Statement Analysis – Financial Results
- GBLT Corp. (GBLTF) Income Statement Analysis – Financial Results
Syndax Pharmaceuticals, Inc. (SNDX)
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 12.00K | 454.00K | 456.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.00K |
| Gross Profit | -12.00K | -454.00K | 139.25M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | -51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 163.02M | 118.50M | 88.25M | 50.44M | 42.99M | 60.11M | 48.20M | 31.67M | 9.55M | 10.18M | 3.21M | 5.24M | 6.09M |
| General & Administrative | 0.00 | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.92M | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 3.49M |
| Other Expenses | 0.00 | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -37.00K | 4.00K | -3.01M | -1.00K | 0.00 |
| Operating Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.57M |
| Cost & Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.62M |
| Interest Income | 21.16M | 5.87M | 403.00K | 841.00K | 1.57M | 0.00 | 0.00 | 0.00 | 161.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 208.00K | 3.14M | 1.90M | 2.36M | 1.57M | 1.94M | 1.42M | 956.00K | 1.58M | 0.00 | 0.00 | 0.00 | 1.99M |
| Depreciation & Amortization | 12.00K | 454.00K | 456.00K | 515.00K | 451.00K | 78.00K | 76.00K | 89.00K | 21.00K | 15.00K | 13.00K | 34.00K | 51.00K |
| EBITDA | -229.94M | -151.76M | 27.28M | -70.29M | -55.60M | -73.88M | -61.88M | -43.68M | -20.49M | -21.32M | -8.56M | -5.26M | -11.05M |
| EBITDA Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,248.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -229.95M | -151.76M | 26.22M | -71.42M | -57.54M | -75.88M | -61.95M | -43.77M | -20.51M | -21.33M | -8.57M | -8.73M | -9.62M |
| Operating Income Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,271.61% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 20.59M | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -3.61M | 1.50M | -5.60M | -1.23M | -3.47M |
| Income Before Tax | -209.36M | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Income Before Tax Ratio | 0.00% | 0.00% | 17.84% | -4,822.54% | -3,694.59% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.59M | -43.00K | -89.00K | -92.00K | 1.92M | -76.00K | -89.00K | 1.54M | -1.50M | 2.59M | 1.23M | 0.00 |
| Net Income | -209.36M | -143.75M | 24.93M | -73.07M | -55.96M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Net Income Ratio | 0.00% | 0.00% | 17.84% | -4,816.68% | -3,688.53% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.98 | -2.37 | 0.48 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| EPS Diluted | -2.98 | -2.37 | 0.46 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| Weighted Avg Shares Out | 70.26M | 60.76M | 52.06M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
| Weighted Avg Shares Out (Dil) | 70.37M | 60.76M | 53.62M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , Sept. 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on September 1, 2023 the Company granted inducement awards to purchase up to 149,200 shares...
Syndax Announces Participation at the Citi 18th Annual BioPharma Conference
WALTHAM, Mass. , Aug. 31, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, IR Michael Metzger - CEO Neil Gallagher - President & Head, R&D Keith Goldan - CFO Peter Ordentlich...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , Aug. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on August 1, 2023 the Company granted inducement awards to purchase up to 118,000 shares of...
Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
– Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two...
Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023
WALTHAM, Mass. , July 25, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2023 financial results and provide a business update...
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
– Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg administered every two weeks – – Data highlight durable response to treatment. At the 0.3 mg/kg dose,...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , July 7, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on July 1, 2023 the Company granted inducement awards to purchase up to 31,400 shares...
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&D Keith Goldan...
Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023
WALTHAM, Mass. , May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2023 financial results and provide a business update...
Source: https://incomestatements.info
Category: Stock Reports